# Non-Articular Osseous Sarcoidosis: A Rare Case of Active Sarcoidosis with Progressive Lung Lesions and Normal Inflammation Biomarkers

**Authors:** Jing Zhang, Yu Hu, Peixin Dong, Hefang Guo, Lixia Huang, Lili Chen, Yanbin Zhou

PMC · DOI: 10.3390/diagnostics15091135 · 2025-04-29

## TL;DR

A rare case of sarcoidosis with bone and lung involvement and normal inflammation markers is described, highlighting the need for better diagnostic tools and combination therapy.

## Contribution

Presents a rare case of non-articular osseous sarcoidosis with normal biomarkers and atypical treatment response.

## Key findings

- The patient had progressive lung and bone lesions with persistently normal inflammatory biomarkers.
- Diagnosis was confirmed via lung and bone biopsies after failed tuberculosis and glucocorticoid treatments.
- Combination therapy with prednisone and methotrexate was required to manage persistent symptoms.

## Abstract

Sarcoidosis is a rare multisystem inflammatory disease characterized by non-necrotizing granulomas, typically affecting the lungs, lymph nodes, skin, and bones. Due to its extreme clinical heterogeneity, diagnosis remains challenging. Within the skeletal system, the thoracic spine, ankles, and knees are the most commonly involved joints. We report a rare case of non-articular osseous sarcoidosis with progressive pulmonary lesions and persistently normal inflammatory biomarkers (ACE, CRP, ESR, IL-2, and TNF-α) that required differentiation from metastatic bone tumors and tuberculosis. Prior to presentation at our hospital, the patient did not respond to six months of anti-tuberculosis treatment and one month of systemic glucocorticoid therapy in three other hospitals. Based on lung and bone biopsies, she was finally diagnosed as having active sarcoidosis in our hospital. Despite 3 months of prednisone, pulmonary consolidation and bone lesions persisted until methotrexate was added. This case highlights the preference of combined glucocorticoid and methotrexate therapy for sarcoidosis with atypical osseous involvement and normal biomarkers, underscoring the urgent need for novel diagnostic tools to mitigate misdiagnosis.

## Linked entities

- **Chemicals:** prednisone (PubChem CID 5865), methotrexate (PubChem CID 4112)
- **Diseases:** sarcoidosis (MONDO:0008399), tuberculosis (MONDO:0018076)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}
- **Diseases:** Non-Articular Osseous Sarcoidosis (MESH:D012507), Inflammation (MESH:D007249), bone tumors (MESH:D001859), Lung Lesions (MESH:D008171), granulomas (MESH:D006099), tuberculosis (MESH:D014376), bone lesions (MESH:D001847)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12071815/full.md

---
Source: https://tomesphere.com/paper/PMC12071815